MTOR and neoplasm: Among several surrogate markers assessing mTOR inhibition in skin, peripheral blood mononuclear cells, and/or in the tumor cells, a decrease in the p-S6K has been reported as the most reliable pharmacodynamical biomarker in preclinical studies and clinical trials [8].